KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Clover Health Investments (CLOV) EBIT Margin (2020 - 2025)

Clover Health Investments' EBIT Margin history spans 6 years, with the latest figure at 10.11% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 410.0% year-over-year to 10.11%; the TTM value through Dec 2025 reached 4.46%, down 116.0%, while the annual FY2025 figure was 4.44%, 111.0% down from the prior year.
  • EBIT Margin reached 10.11% in Q4 2025 per CLOV's latest filing, down from 4.91% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2.02% in Q2 2024 to a low of 92.92% in Q4 2021.
  • Average EBIT Margin over 5 years is 19.32%, with a median of 10.06% recorded in 2022.
  • Peak YoY movement for EBIT Margin: plummeted -5756bps in 2021, then soared 8465bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 92.92% in 2021, then surged by 91bps to 8.27% in 2022, then crashed by -152bps to 20.83% in 2023, then soared by 71bps to 6.01% in 2024, then tumbled by -68bps to 10.11% in 2025.
  • Per Business Quant, the three most recent readings for CLOV's EBIT Margin are 10.11% (Q4 2025), 4.91% (Q3 2025), and 2.21% (Q2 2025).